CellVoyant
AI NativeWe see the future in cells
Est 2021|Raised $12.6M
We see the future in cells
Published Aug 14, 2026
Press coverage and partnership announcements indicate increasing visibility and some commercial traction, but the absence of broad third-party review data limits the ability to infer widespread adoption.
| Starting Price | Not publicly listed (trial/demo and quote-based engagements) | Not publicly listed (often hardware + software; quote-based) | Not publicly listed (typically instrument + software) |
| Primary Use Case | Predicting current and future cell states/CQAs from label-free microscopy and supporting process optimization workflows | Live-cell imaging and morphology-based phenotyping; in some offerings, integrates with sorting/phenotyping workflows | Label-free time-lapse assays using quantitative phase imaging (QPI) for measurement-centric workflows |
| Key Strength | Focus on forecasting future states and on optimization workflows that can integrate with automation (based on vendor materials) | Emphasis on real-time imaging, phenotyping, and sorting capabilities in certain configurations | QPI measurement provides high-contrast, label-free readouts for time-lapse assays |
| Key Weakness | Limited independent review coverage; limited publicly documented security/compliance details; pricing not public | May require specialized hardware and tailored workflows; may be less focused on forecasting cell fate for manufacturing CQAs | Primarily measurement and assay-centric and may not provide the same predictive optimization workflow claims |
—